Onco-Innovations Appoints Dr. Michael Lock to Scientific & Clinical Advisory Board
VANCOUVER, BC / ACCESS Newswire / September 22, 2025 / Onco-Innovations Limited (CBOE CA:ONCO)(Frankfurt:W1H, WKN: A3EKSZ)(OTCQB:ONNVF) ("Onco" or the "Company")...
Clinical Trial
Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis
BARCELONA, Spain and DÜSSELDORF, Germany, Sept. 22, 2025 /PRNewswire/ -- Neuraxpharm Group (Neuraxpharm), a leading European pharmaceutical company focused on...
The Digital Medicine Society Unveils Healthcare 2030 — A Blueprint to Transform U.S. Healthcare in the Digital Era
Launch coincides with the Healthcare 2030 Summit in Washington, DC, bringing together top government officials, industry leaders, and patient advocates...
BYOD or Bust: Are Clinical Trials Ready for the Device Revolution? Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into the current landscape of "Bring Your Own Device" (BYOD) adoption across therapeutic areas...
Enhancing Clinical Trials in Obesity by Integrating Clinical Outcome Assessments and Digital Health Technologies, Upcoming Webinar Hosted by Xtalks
In this free webinar, gain insight into patterns in the current use of clinical outcome assessment (COA) and digital health...
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with...
Actuate Therapeutics Provides FDA with Updated Clinical Data Package to Support Planned Regulatory Interactions with FDA and EMA Over the Coming Months
Elraglusib represents a potential back bone therapy in pancreatic cancer with three ongoing trials in combination with current standards of...
NetraMark Initiates AI-Driven Collaboration in Glioblastoma Research
TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0)...
Integra LifeSciences Strengthens Leadership with Appointment of New Chief Medical Officer
Dr. Raymond Turner is a board-certified endovascular neurosurgeon with more than 20 years of surgical practice Dr. Raymond Turner Dr. Turner...
CRISPR Therapeutics and Sirius Therapeutics Announce First Patient Dosed in Phase 2 Trial of SRSD107 for Thromboembolic Disorders in Europe
ZUG, Switzerland and BOSTON and SAN DIEGO and SHANGHAI, Sept. 22, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based...
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain
LONDON and NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which...
IMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key...
Allarity Therapeutics Presents New Phase 2 Clinical Data for Stenoparib/2X-121 Showing Landmark Median Overall Survival Has Now Surpassed 25 Months
- Kaplan-Meier analyses show for the first time that median Overall Survival exceeds 25 months for Platinum Resistant and Refractory Ovarian...
Beyond Air to Participate in the ROTH 4th Annual Healthcare Opportunities Conference
GARDEN CITY, N.Y., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a...
Corbus Pharmaceuticals to Host In-Person and Virtual KOL Event at ESMO 2025
KOL Panel to Discuss Data from Dose Optimization Clinical Trial of CRB-701NORWOOD, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Corbus...
ORYZON to Sponsor First Phelan-McDermid Syndrome (PMS) Burden of Illness Study
Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system...
BioCardia Announces Positive Preliminary Clinical Consultation with Japan Pharmaceutical and Medical Device Agency on Cell Therapy for Ischemic Heart Failure
SUNNYVALE, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. , a developer of cellular and cell-derived therapeutics for the...
MediciNova Announces Completion of Patient Enrollment in COMBAT-ALS Phase 2b/3 Clinical Trial of MN-166 (ibudilast)
~Patient Recruitment Closed~LA JOLLA, Calif., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ...
Adverum Biotechnologies Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-vec for Wet Age-Related Macular Degeneration
Screening closing ahead of expectations, with full enrollment now anticipated in 4Q 2025 (previously 1Q 2026)ARTEMIS topline data readout accelerated...
New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-‘749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed
Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with...